The heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus

Abstract

Given the growing interest in the metabolic heterogeneity of hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). This study comprehensively analysed the metabolic heterogeneity of HCC, PVTT, and normal liver samples using multi-omics combinations. A single-cell RNA sequencing dataset encompassing six major cell types was obtained for integrated analysis. The optimal subtypes were identified using cluster stratification and validated using spatial transcriptomics and fluorescent multiplex immunohistochemistry. Then, a combined index based meta-cluster was calculated to verify its prognostic significance using multi-omics data from public cohorts. Our study first depicted the metabolic heterogeneity landscape of non-malignant cells in HCC and PVTT at multiomics levels. The optimal subtypes interpret the metabolic characteristics of PVTT formation and development. The combined index provided effective predictions of prognosis and immunotherapy responses. Patients with a higher combined index had a relatively poor prognosis (p <0.001). We also found metabolism of polyamines was a key metabolic pathway involved in conversion of metabolic heterogeneity in HCC and PVTT, and identified ODC1 was significantly higher expressed in PVTT compared to normal tissue (p =0.03). Our findings revealed both consistency and heterogeneity in the metabolism of non-malignant cells in HCC and PVTT. The risk stratification based on cancer-associated fibroblasts and myeloid cells conduce to predict prognosis and guide treatment. This offers new directions for understanding disease development and immunotherapy responses.

References

[1] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.

[2] EASL Clinical PracticeGuidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.

[3] TaoZW, ChengBQ, ZhouT, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: a narrative review. Hepatobiliary Pancreat Dis Int. 2022;21:134-144.

[4] ZhangXP, GaoYZ, ChenZH, et al. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology. 2019;69:2076-2090.

[5] ZouYW, RenZG, SunY, et al. The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2023;22:54-63.

[6] DengZJ, LiL, TengYX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol. 2022;10:147-158.

[7] LlovetJM, De Baere T, KulikL, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293-313.

[8] ZhangM, DingQ, BianC, Su J, XinY, JiangX. Progress on the molecular mechanism of portal vein tumor thrombosis formation in hepatocellular carcinoma. Exp Cell Res. 2023;426:113563.

[9] YaoB, LiY, ChenT, et al. Hypoxia-induced cofilin 1 promotes hepatocellular carcinoma progression by regulating the PLD1/AKT pathway. Clin Transl Med. 2021;11:e366.

[10] LobelGP, JiangY, SimonMC. Tumor microenvironmental nutrients, cellular responses, and cancer. Cell Chem Biol. 2023;30:1015-1032.

[11] XiaL, OyangL, LinJ, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.

[12] XuY, ZhangZ, XuD, YangX, ZhouL, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int. 2021;21:409.

[13] Martínez-ReyesI, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669-680.

[14] StineZE, SchugZT, SalvinoJM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141-162.

[15] LiZ, SunC, QinZ. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11:8322-8336.

[16] VitaleI, ManicG, CoussensLM, Kroemer G, GalluzziL. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36-50.

[17] LeoneRD, PowellJD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516-531.

[18] SchwörerS, Vardhana SA, ThompsonCB. Cancer metabolism drives a stromal regenerative response. Cell Metab. 2019;29:576-591.

[19] PranziniE, Pardella E, PaoliP, FendtSM, TaddeiML. Metabolic reprogramming in anticancer drug resistance: a focus on amino acids. Trends Cancer. 2021;7:682-699.

[20] ZhengL, QinS, SiW, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474.

[21] ThorssonV, GibbsDL, BrownSD, et al. The immune landscape of cancer. Immunity. 2018;48:812-830.e814.

[22] LuoH, XiaX, HuangLB, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13:6619.

[23] GalboPM Jr, ZangX, ZhengD. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27:2636-2647.

[24] SunY, WuL, ZhongY, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404-421.e416.

[25] Perez-GraciaJL, LoriotY, RosenbergJE, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens. Eur Urol. 2018;73:462-468.

[26] MariathasanS, TurleySJ, NicklesD, et al. TGFβattenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544-548.

[27] Van AllenEM, MiaoD, SchillingB, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-211.

[28] LiuD, Schilling B, LiuD, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916-1927.

[29] RoseTL, WeirWH, MayhewGM, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125:1251-1260.

[30] WuR, GuoW, QiuX, et al. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv. 2021;7:eabg3750.

[31] ParkKY, LiWA, PlattMO. Patient specific proteolytic activity of monocyte-derived macrophages and osteoclasts predicted with temporal kinase activation states during differentiation. Integr Biol. 2012;4:1459-1469.

[32] LiX, WangCY. From bulk, single-cell to spatial RNA sequencing. Int J Oral Sci. 2021;13:36.

[33] PavlovaNN, ZhuJ, ThompsonCB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355-377.

[34] XuK, XiaP, ChenX, Ma W, YuanY. ncRNA-mediated fatty acid metabolism reprogramming in HCC. Trends Endocrinol Metab. 2023;34:278-291.

[35] ZhouQ, AnY, LiuT, et al. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia. 2022;39:97-107.

[36] YuanY, HeW, YangZ, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109:1222-1230.

[37] DingX, SunW, LiW, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study. Cancer. 2021;127:3782-3793.

[38] RivlinRS. Riboflavin and cancer: a review. Cancer Res. 1973;33:1977-1986.

[39] ZhuX, XuP, ZhuR, et al. Multi-kingdom microbial signatures in excess body weight colorectal cancer based on global metagenomic analysis. Commun Biol. 2024;7:24.

[40] GanC, HuangX, WuY, et al. Untargeted metabolomics study and pro-apoptotic properties of B-norcholesteryl benzimidazole compounds in ovarian cancer SKOV3 cells. J Steroid Biochem Mol Biol. 2020;202:105709.

[41] GoswamiS, Anandhan S, RaychaudhuriD, SharmaP. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023;23:106-120.

[42] MantovaniA, Allavena P, MarchesiF, GarlandaC. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799-820.

[43] BarryST, Gabrilovich DI, SansomOJ, CampbellAD, MortonJP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023;23:216-237.

[44] ChenS, SaeedA, LiuQ, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8:207.

[45] ZhangX, JiL, LiMO. Control of tumor-associated macrophage responses by nutrient acquisition and metabolism. Immunity. 2023;56:14-31.

[46] NaYR, Stakenborg M, SeokSH, MatteoliG. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531-543.

[47] HeZ, WangJ, ZhuC, et al. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis. Cancer Lett. 2022;548:215751.

[48] HuangJ, PanH, SunJ, et al. TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages. J Exp Clin Cancer Res. 2023;42:286.

[49] ZhouC, WengJ, LiuC, et al. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164:1261-1278.

[50] TanJ, FanW, LiuT, et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126-140.

[51] HaoX, ZhengZ, LiuH, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463.

[52] MaL, Heinrich S, WangL, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022;13:7533.

[53] LiuY, LiangG, XuH, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33:1221-1233.e1211.

[54] SharmaNS, GuptaVK, GarridoVT, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020;130:451-465.

[55] ChengS, HuG, JinZ, WangZ, XueH. CT-based radiomics nomogram for prediction of survival after transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma and portal vein tumor thrombus. Eur Radiol. 2023;33:8715-8726.

[56] LinW, ChenL, ZhangH, et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14:265.

[57] SunR, YangY, LüW, et al. Single-cell transcriptomic analysis of normal and pathological tissues from the same patient uncovers colon cancer progression. Cell Biosci. 2023;13:62.

[58] ZhangH, LiX, LiuZ, et al. Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc-ODC1 nexus. Cancer Metab. 2024;12:7.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.